FRA
GMAB icon

Front Row Advisors’s Genmab GMAB Stock Holding History

Front Row Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-154
Closed -$3.87K – 642
2024
Q2 		$3.87K Buy
154
+7
+5% +$198 ﹤0.01% 771
2024
Q1 		$4.4K Buy
+147
New +$4.32K ﹤0.01% 755
2023
Q4 		– Sell
-145
Closed -$5.11K – 607
2023
Q3 		$5.11K Buy
145
+4
+3% +$152 ﹤0.01% 666
2023
Q2 		$5K Sell
141
-4
-3% -$159 ﹤0.01% 664
2023
Q1 		$5K Buy
145
+2
+1% +$77 ﹤0.01% 665
2022
Q4 		$6K Sell
143
-92
-39% -$3.79K ﹤0.01% 605
2022
Q3 		$8K Buy
235
+10
+4% +$351 ﹤0.01% 540
2022
Q2 		$7K Buy
225
+3
+1% +$97 ﹤0.01% 584
2022
Q1 		$8K Buy
222
+5
+2% +$172 ﹤0.01% 595
2021
Q4 		$9K Sell
217
-5
-2% -$208 ﹤0.01% 601
2021
Q3 		$10K Hold
222
– – ﹤0.01% 561
2021
Q2 		$10K Buy
222
+7
+3% +$270 ﹤0.01% 565
2021
Q1 		$7K Sell
215
-2
-0.9% -$75 ﹤0.01% 634
2020
Q4 		$9K Sell
217
-2
-0.9% -$75 ﹤0.01% 538
2020
Q3 		$8K Buy
+219
New +$7.92K ﹤0.01% 560

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Front Row Advisors's GMAB Position: Q3 2024 in Review

Front Row Advisors sold out of Genmab (GMAB) in Q3 2024, closing a stake of 154 shares — an estimated $3.87K sold.

Front Row Advisors first reported a position in GMAB in Q3 2020 and held it in 15 quarters. The position peaked at $10K in Q3 2021. 223 funds tracked by Wall St. Rank hold GMAB as of Q3 2024.

  • Front Row Advisors reported no remaining Genmab position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 154 Genmab shares in Q3 2024, an estimated $3.87K.
  • Front Row Advisors first reported a position in Genmab in Q3 2020 and held it in 15 quarters.
  • Front Row Advisors's Genmab position peaked at $10K in Q3 2021.
  • 223 funds tracked by Wall St. Rank held Genmab as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.